arrow
A

Alexandria P. Cogdill

The University of Texas MD Anderson Cancer Center
H指数:30
被引数:2.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy
Nature
IF48.5
2022-06-150
PRE
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

肠道菌群特征与联合CTLA-4和PD-1阻断的毒性有关

2021-07-08251
OAAI
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response

膳食纤维和益生菌影响肠道微生物组和黑色素瘤免疫治疗反应

Science
IF45.8
2021-01-010
OA
Immunodynamics of explanted human tumors for immuno-oncology
2020-12-2910
OAAI
Elucidating the gut microbiota composition and the bioactivity of immunostimulatory commensals for the optimization of immune checkpoint inhibitors
2020-07-208
OAAI
CONSTRUCTION OF THE IMMUNE LANDSCAPE OF DURABLE RESPONSE TO CHECKPOINT BLOCKADE THERAPY BY INTEGRATING PUBLICLY AVAILABLE DATASETS
2020-04-150
OAAI
The human tumor microbiome is composed of tumor type–specific intracellular bacteria

人类肿瘤微生物组由肿瘤类型特异性细胞内细菌组成

Science
IF45.8
2020-01-010
OAAI
Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies

联合anti-CTLA-4加anti-PD-1检查点阻断利用与单一疗法部分不同的细胞机制

2019-10-21240
OAAI
The gut microbiome (GM) and immunotherapy response are influenced by host lifestyle factors
2019-07-0149
OA
Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas
2018-12-01151
OAAI
Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

肠道菌群调节黑色素瘤患者对anti-PD-1免疫治疗的反应

Science
IF45.8
2017-01-010
OAAI
Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma
IMMUNITY
IF26.3
2016-06-01516
OA
Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice

亲和力调节的ErbB2或EGFR嵌合抗原受体T细胞对小鼠肿瘤的治疗指数增加

2015-08-31512
OAAI
Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma
2015-02-18426
OAAI